ROCKVILLE, MD, October 15, 2015 – Therabron Therapeutics, Inc., a specialty biotechnology company dedicated to redefining the management of respiratory disease through innovation, today announced that it will participate in two upcoming investor conferences. Click here for more information.
Recent Posts
- Therabron Therapeutics Receives Orphan Drug Designation in the European Union for CG367.
- Therabron Therapeutics to Present at Stifel 2016 Healthcare Conference
- Therabron Therapeutics Receives from FDA Rare Pediatric Disease Designation for Lead Phase 2 Program in Preterm Infants
- Therabron Therapeutics to Present at Upcoming Industry and Investor Conferences
- Therabron Therapeutics Completes Enrollment of Phase 2 Clinical Trial for Lead Product Candidate CG100 for the Prevention of Chronic Lung Disease in Preterm Infants